AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback